Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Ha, Seon Ah ^a   Lee, Youn Soo ^a   Shin, Seung Min ^a   Kim, Hyun Kee ^a   Kim, Sanghee ^a   Namkoong, Hong ^a   Kim, Hae Joo ^a   Jung, Sang Min ^a   Lee, Yu Sun ^a   Chung, Yeun Jun ^a   Jung, Sang Seol ^a   Kim, Jin Woo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN HCCR 1; PROTEIN P53; REGULATOR PROTEIN; UNCLASSIFIED DRUG; LETMD1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER TISSUE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PROTEIN EXPRESSION; TUMOR MARKER; UPREGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; METABOLISM; NORTHERN BLOTTING; TUMOR CELL LINE;

BLOTTING, NORTHERN; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 65449123470     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-51     Document Type: Article

References (31)

1. Ko J Lee YH Hwang SY Lee YS Shin SM Hwang JH Kim J Kim YW Jang SW Ryoo ZY Kim IK Namkoong SE Kim JW Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization Oncogene 2003, 22:4679-4689. 10.1038/ sj.onc.1206624 12879013
2. Jung SS Park HS Lee IJ Namkoong H Shin SM Cho GW Ha SA Park YG Lee YS Ko J Kim JW The HCCR oncoprotein as a biomarker for human breast cancer Clin Can Res 2005, 11:7700-7708. 10.1158/1078-0432.CCR-04-2609
3. Lamerz R Stieber P Fateh-Moghadam A Serum marker combinations in human breast cancer (review) In Vivo 1993, 7(6B):607-613. 8193281
4. Schechter AL Stern DF Vaidyanathan L Decker SJ Drebin JA Greene MI Weinberg RA The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen Nature 1984, 312:513-516. 10.1038/312513a0 6095109
5. Ellis MJ Coop A Singh B Mauriac L Llombert-Cussac A Jänicke F Miller WR Evans DB Dugan M Brady C Quebe-Fehling E Borgs M Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial J Clin Oncol 2001, 19:3808-3816. 11559718
6. Ménard S Valagussa P Pilotti S Gianni L Biganzoli E Boracchi P Tomasic G Casalini P Marubini E Colnaghi MI Cascinelli N Bonadonna G Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables J Clin Oncol 2001, 19:329-335. 11208823
7. Hudis CA Trastuzumab-Mechanism of action and use in clinical practice N Engl J Med 2007, 357:39-51. 10.1056/NEJMra043186 17611206
8. Yarden Y Sliwkowski MX Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073 11252954
9. Cho GW Shin SM Namkoong H Kim HK Ha SA Hur SY Kim TE Chai YG Kim JW The phosphatidylinositol 3-kinase/Akt pathway regulates the HCCR-1 oncogene expression Gene 2006, 384:18-26. 10.1016/j.gene.2006.07.006 16949218
10. Bacus SS Gudkov AV Esteva FJ Yarden Y Expression of erbB receptors and their ligands in breast cancer: Implications to biological behavior and therapeutic response Breast Dis 1999, 11:63-75. 15687593
11. Borresen-Dale AL TP53 and breast cancer Hum Mutat 2003, 21:292-300. 10.1002/humu.10174 12619115
12. Colditz GA Rosner BA Chen WY Holmes MD Hankinson SE Risk Factors for Breast Cancer According to Estrogen and Progesterone Receptor Status J Natl Cancer Inst 2004, 96:218-228. 14759989
13. Slamon DJ Clark GM Wong SG Levin WJ Ullrich A McGuire WL Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987, 235:177-182. 10.1126/science.3798106 3798106
14. Demonty G Bernard-Marty C Puglisi F Mancini I Piccart M Progress and new standards of care in the management of HER-2 positive breast cancer Eur J Cancer 2007, 43:497-509. 10.1016/j.ejca.2006.10.020 17223541
15. Suo Z Daehli KU Lindboe CF Borgen E Bassarova A Nesland JM Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients Int J Surg Pathol 2004, 12:311-318. 10.1177/106689690401200404 15494857
16. Raab G Hoegel B Biebl J Eiermann W Chromogen in situ hybridisation (CISH) for HER2 assessment is highly concordant with FISH in core cut biopsies of primary T2 breast cancers J Clin Oncol 2004, 22:14.
17. Tsuda H HER-2 (c-erbB-2) test update: Present status and problems Breast Cancer 2006, 13:236-248. 10.2325/jbcs.13.236 16929116
18. Viani GA Afonso SL Stefano EJ De Fendi LI Soares FV Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: A meta-analysis of published randomized trials BMC Cancer 2007, 7:153. 1959236 17686164 10.1186/1471-2407-7-153
19. Mass RD Press MF Anderson S Cobleigh MA Vogel CL Dybdal N Leiberman G Slamon DJ Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab Clin Breast Cancer 2005, 6:240-246. 10.3816/CBC.2005.n.026 16137435
20. Ross JS Fletcher JA Bloom KJ Linette GP Stec J Clark E Ayers M Symmans WF Pusztai L Hortobagyi GN HER-2/neu testing in breast cancer Am J Clin Pathol 2003, 120(Suppl):S53-S71. 15298144
21. Yaziji H Goldstein LC Barry TS Werling R Hwang H Ellis GK Gralow JR Livingston RB Gown AM HER-2 testing in breast cancer using parallel tissue-based methods JAMA 2004, 291:1972-1977. 10.1001/jama.291.16.1972 15113815
22. Vera-Román JM Rubino-Martínez LA Comparative assays for the HER-2/neu oncogene status in breast cancer Arch Pathol Lab Med 2004, 128:627-633. 15163239
23. Choi DH Shin DB Lee MH Lee DW Dhandapani D Carter D King BL Haffty BG A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma Cancer 2003, 98:1587-1595. 10.1002/cncr.11703 14534873
24. Carlson RW Moench SJ Hammond ME Perez EA Burstein HJ Allred DC Vogel CL Goldstein LJ Somlo G Gradishar WJ Hudis CA Jahanzeb M Stark A Wolff AC Press MF Winer EP Paik S Ljung BM NCCN HER2 Testing in Breast Cancer Task Force HER2 testing in breast cancer: NCCN task force report and recommendations J Natl Compr Canc Netw 2006, 4 Suppl 3:S1-S22. 16813731
25. Haines GK 3rd Wiley E Susnik B Apple SK Frkovic-Grazio S Reyes C Goldstein LC Dadmanesh F Gown AM Nadji M Bracko M Tavassoli FA HER2 in well differentiated breast cancer: Is testing necessary? Breast Cancer Res Treat 2008. 18202913
26. Cordon-Cardo C Dalbagni G Saez GT Oliva MR Zhang ZF Rosai J Reuter VE Pellicer A p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns Int J Cancer 1994, 56:347-353. 10.1002/ ijc.2910560309 7906253
27. Colomer R Montero S Lluch A Ojeda B Barnadas A Casado A Massutí B Cortés-Funes H Lloveras B Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer Clin Cancer Res 2000, 6:2356-2362. 10873087
28. Lebeau A Deimling D Kaltz C Sendelhofert A Iff A Luthardt B Untch M Löhrs U HER-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization J Clin Oncol 2001, 19:354-363. 11208826
29. Wolff AC Hammond ME Schwartz JN Hagerty KL Allred DC Cote RJ Dowsett M Fitzgibbons PL Hanna WM Langer A McShane LM Paik S Pegram MD Perez EA Press MF Rhodes A Sturgeon C Taube SE Tubbs R Vance GH Vijver van de M Wheeler TM Hayes DF American Society of Clinical Oncology; College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 2007, 25:118-145. 10.1200/JCO.2006.09.2775 17159189
30. Perez EA Suman VJ Davidson NE Martino S Kaufman PA Lingle WL Flynn PJ Ingle JN Visscher D Jenkins RB HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial J Clin Oncol 2006, 24:3032-3038. 10.1200/JCO.2005.03.4744 16809727
31. Santinelli A Baccarini M Colanzi P Stramazzotti D Fabris G Immunohistochemical evaluation of HER-2/neu expression in infiltrating breast carcinoma: A study of reproducibility Anal Quant Cytol Histol 2002, 24:54-62. 11865950